Breo Ellipta misses in Phase III SUMMIT study

Theravance Inc. (NASDAQ:THRX) tumbled $2.43 (15%) to $13.56 on Tuesday after Breo Ellipta fluticasone furoate/vilanterol failed to significantly improve survival

Read the full 203 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE